Literatur
- 1
Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Spengler U, Goeser T,
Pape G, Hopf U, Zeuzem S.
Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously
untreated patients with chronic hepatitis C: results of a double-blind, placebo-controlled
trial.
J Hepatol.
2002;
36
(Suppl)
3
- 2
Fried M W, Shiffman M L, Reddy R K. et al .
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection.
N Engl J Med.
2002;
347
975-982
- 3
Glue P, Fang J W, Rouzier-Panis R, Raffanel C, Sabo R, Gupta S K, Salfi M, Jacobs S.
Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary
efficacy data.
Clin Pharmacol Ther.
2000;
68
556-567
- 4
Hadziyannis S J, Cheinquer H, Morgan T, Diago M, Jensen D M, Sette H, Ramadori G,
Bodenheimer H C, Marcellin P, Lee S -D, Roberts P J, Ackrill A M.
Peginterferon alfa-2a (40KD) (Pegasys) in combination with ribavirin (RBV): efficacy
and safety results from a phase III, randomized, double-blind, multicentre study
examining effect of duration of treatment and RBV dose.
J Hepatol.
2002;
36
(Suppl 1)
3
- 5
Herrmann E, Neumann A U, Schmidt J M, Zeuzem S.
Hepatitis C virus kinetics.
Antivir Ther.
2000;
5
85-90
- 6
Lindsay K L, Trepo C, Heintges T, Shiffman M L, Gordon S C, Hoefs J C, Schiff E R,
Goodman Z D, Laughlin M, Yao R, Albrecht J K.
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon
alfa-2b as initial treatment for chronic hepatitis C.
Hepatology.
2001;
34
395-403
- 7
Manns M P, McHutchison J G, Gordon S C, Rustgi V K, Shiffman M, Reindollar R, Goodman Z D,
Koury K, Ling M, Albrecht J K.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin
for initial treatment of chronic hepatitis C: a randomised trial.
Lancet.
2001;
358
958-65
- 8
McHutchison J G, Gordon S C, Schiff E R, Shiffman M L, Lee W M, Rustgi V K, Goodman Z D,
Ling M H, Cort S, Albrecht J K.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for
chronic hepatitis C.
N Engl J Med.
1998;
339
1485-1492
- 9
Niederau C.
Therapie der chronischen Hepatitis C mit pegylierten Alpha-Interferonen.
Dtsch Med Wochenschr.
2002;
127
563-566
- 10
Poynard T, Marcellin P, Lee S S, Niederau C, Minuk G S, Ideo G, Bain V, Heathcote J,
Zeuzem S, Trepo C, Albrecht J.
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks
versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection
with hepatitis C virus.
Lancet.
1998;
352
1426-1432
- 11
Reddy K R, Wright T L, Pockros P J. et al .
Efficacy and safety of pegylated (40 kd) interferon alfa-2a compared with interferon
alfa-2a in noncirrhotic patients with chronic hepatitis C.
Hepatology.
2001;
33
433-438
- 12
Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P,
Poynard T.
Modeling the impact of interferon alfa treatment on liver fibrosis progression in
chronic hepatitis C: a dynamic view.
Gastroenterology.
1999;
116
378-386
- 13
Xu Z X, Patel I, Joubert P.
Single-dose safety/tolerability and pharmacokinetics/ pharmacodynamics (PK/PD) following
administration of ascending subcutaneous doses of pegylated interferon (PEG-IFN)
and interferon alfa-2a (IFN alfa-2a) to healthy subjects.
Hepatology.
1998;
28
(Suppl)
702
- 14
Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M,
Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M.
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance
program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan.
Inhibition of hepatocarcinogenesis by interferon therapy.
Ann Intern Med.
1999;
131
174-181
- 15
Wedemeyer H, Cornberg M, Manns M P.
PEG-Interferone: Bedeutung für die Therapie der Virushepatitis B und C.
Dtsch Med Wochenschr.
2001;
S126
68-75
- 16
Zeuzem S, Feinman S V, Rasenack J, Heathcote E J, Lai M Y, Gane E, O’Grady J, Reichen J,
Diago M, Lin A, Hoffman J, Brunda M J.
Peginterferon alfa-2a in patients with chronic hepatitis C.
N Engl J Med.
2000;
343
1666-1672
- 17
Zeuzem S, Herrmann E, Lee J H, Fricke J, Neumann A U, Modi M, Colucci G, Roth W K.
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon
alpha2a.
Gastroenterology.
2001;
120
1438-1447
Prof. Dr. med. Stefan Zeuzem
Klinik für Innere Medizin II mit den Schwerpunkten, Gastroenterologie, Hepatologie
und Endokrinologie, Universitätskliniken des Saarlandes
Kirrberger Straße
Gebäude 41
66421 Homburg/Saar
Phone: 06841/1623201
Fax: 06841/1623267
Email: Zeuzem@uniklinik-saarland.de
